AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

9.080

-0.670-6.87%

Volume:3.26M

Turnover:30.23M

Market Cap:3.08B

PE:151.57

High:9.590

Open:9.590

Low:9.050

Close:9.750

52wk High:31.970

52wk Low:9.050

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.34

T/O Rate:1.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.060

EPS(LYR):0.203

ROE:3.14%

ROA:2.08%

PB:5.19

PE(LYR):44.69

Loading ...

Overview Company News Filings

Company Profile

Company Name:

TELIX PHARMACEUTICALS LTD

Exchange:

ASX

Establishment Date:

2015

Employees:

423

Office Location:

55 Flemington Road,Level 4,North Melbourne,Victoria,Australia

Website:

http://telixpharma.com

Zip Code:

3051

Phone:

Fax:

- -

Introduction:

Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":9.08,"timestamp":1770873120000,"preClose":9.75,"halted":0,"volume":3261701,"delay":0,"changeRate":-0.06871794871794872,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.059912127006964924,"marketStatus":"Post Close","change":-0.67,"latestTime":"02-12 16:16:27 AEDT","open":9.59,"high":9.59,"low":9.05,"amount":30227055,"amplitude":0.055385,"askPrice":9.09,"askSize":2670,"bidPrice":9.08,"bidSize":1069,"shortable":3,"etf":0,"ttmEps":0.059912127006964924,"tradingStatus":3,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770937200000},"marketStatusCode":15,"adr":0,"exchange":"ASX","adjPreClose":9.75,"openAndCloseTimeList":[[1770850800000,1770872400000]],"volumeRatio":1.339519,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.08%","roe":"3.14%","lyrEps":0.203157,"volumeRatio":1.339519,"shares":338721355,"dividePrice":0,"high":9.59,"amplitude":0.055385,"preClose":9.75,"low":9.05,"week52Low":9.05,"pbRate":"5.19","psRate":"3.30","week52High":31.97,"institutionHeld":0,"latestPrice":9.08,"committee":-0.428189,"eps":0.05990732909411239,"divideRate":0,"volume":3261701,"delay":0,"ttmEps":0.05990732909411239,"open":9.59,"prevYearClose":11.2,"prevWeekClose":9.85,"prevMonthClose":10.55,"prevQuarterClose":11.2,"fiveDayClose":10.13,"twentyDayClose":11.1,"sixtyDayClose":14.13,"earningDate":1771430400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":537247297,"yearFounded":2015,"employeeNum":423,"address":"55 Flemington Road,Level 4,North Melbourne,Victoria,Australia","zipCode":"3051","officePhone":"61 3 9093 3855"},"stockCompanyDetail":{"websiteUrl":"http://telixpharma.com","stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":-0.105},{"period":"3month","weight":-0.3262},{"period":"6month","weight":-0.4089},{"period":"1year","weight":-0.6474},{"period":"ytd","weight":-0.1018}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0033},{"period":"3month","weight":0.0114},{"period":"6month","weight":0.0682},{"period":"1year","weight":0.2023},{"period":"ytd","weight":0.0074}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.111111,"avgChangeRate":-0.051353},{"month":2,"riseRate":0.5,"avgChangeRate":-0.010078},{"month":3,"riseRate":0.875,"avgChangeRate":0.143946},{"month":4,"riseRate":0.75,"avgChangeRate":0.105333},{"month":5,"riseRate":0.375,"avgChangeRate":0.040609},{"month":6,"riseRate":0.625,"avgChangeRate":0.069381},{"month":7,"riseRate":0.375,"avgChangeRate":0.037262},{"month":8,"riseRate":0.5,"avgChangeRate":-0.013415},{"month":9,"riseRate":0.75,"avgChangeRate":0.053206},{"month":10,"riseRate":0.75,"avgChangeRate":0.174978},{"month":11,"riseRate":0.222222,"avgChangeRate":-0.024062},{"month":12,"riseRate":0.444444,"avgChangeRate":0.014222}],"exchange":"ASX","name":"TELIX PHARMACEUTICALS LTD","nameEN":"TELIX PHARMACEUTICALS LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":null}}